A smart inhaler device is biosensor laden inhalers with extra digital features. The embedded biosensor is linked to an app on a phone or tablet to help patients and doctors manage their asthma and COPD better. Some smart inhalers have sensors that can work out if a patient is in high pollution or high pollen area, some can send handy reminders, and some can tell if the patient needs to check the inhaler technique. They're all designed to automatically track how often a patient is using an inhaler, so the patient doesn't need to keep records. The wireless data transmission, real-time feedback, alerting mechanism are some of the common features that are incorporated inside a smart inhaler device. Several factors such as rising geriatric population, increasing prevalence of respiratory disorders, rising air pollution and healthcare spending along with escalation in the penetration of smartphones and the internet are driving the market. According to World Health Organisation (WHO), the number of people aged 65 and above is projected to grow from 524 million in 2010 to nearly 1.5 billion in 2050 with the maximum increase in developing countries. The major restraints that are affecting the market of smart inhalers include data security issues and the high cost of smart inhalers. However, the emergence of IoT and Significant Growth in IoMT Market will act as an opportunity for the growth of the market.
A smart inhaler integrates with mobile phones using sensors and Bluetooth technology to track daily usage and alerts patients when missed a dosage. The mobile app may also provide insights into health that may be shared with the doctor. The technology is believed to increase medication adherence which in turn decreases severe flare-ups and emergency hospitalizations. The market is projected to grow from US$ 1,444 Million in 2019 to US$ 4,563.1 Million in 2026 with a high CAGR of 15.72%. Smart inhaler include can be a smart nebulizer and smart inhalers. Smart Inhalers are of two types namely Dry Powdered Inhaler (DPI) and Metered Dose Inhaler (MDI). These devices can be used for both therapeutics and diagnostics as well as monitoring purposes. These devices can be used for drug delivery by patients suffering from asthma and COPD. The end-users in this market can be hospitals & clinics and home care settings. Smart inhaler devices can be delivered to the end-users by online channels and pharmacies that can be located in hospitals or outside.
North America is projected to dominate the smart inhaler market with a market value of US$ 1,904.8 Million (2026) followed by Europe which is projected to constitute a market share of 42% in 2026. Asia-Pacific is projected to show the highest growth during the forecast period.
Presently, there are several novel technologies available on the healthcare market designed to improve respiratory health management and therapeutic compliance. Some of the players that are working in this segment include Boehringer Ingelheim group, Novartis AG, Teva Pharmaceutical Industries Limited, Vectura Group plc, GlaxoSmithKline, 3M Drug Delivery Systems, Adherium Limited, Cohero Health, Inc., AstraZeneca plc, OMRON Healthcare Europe B.V are some of the prominent players of this industry. These players tend to expand their geographical reach by the commencement of several M&As along with partnerships. Moreover, the startup funding has raised enormously in the past few years.
Global Smart Inhalers market stood at US$ 1,655.2 million in 2018. The sector is expected to grow at a CAGR of 15.72% during the forecast period 2020-2025 to reach a market valuation of US$ 4,563.1 million by 2026. North America dominated the Global Smart Inhalers market in 2019, generating revenue of US$ 739.3 million. However, the APAC is expected to witness the highest CAGR growth of 17.43% during the analyzed period.
Global Smart Inhaler Market was valued at US$ 1,655.2 million in 2019 and is anticipated to reach US$ 4,563.1 million by 2026 displaying an elevated CAGR of 15.7% over the forecast period (2020-2026). Smart inhalers are the devices that are used for delivering a variety of medication through inhalation. The drugs used in the inhalers include anti-cholinergic, glucocorticoids, insulin, and beta-agonists for the treatment and prevention of respiratory diseases such as asthma and chronic obstructive pulmonary diseases. The global smart inhalers market trends have gained momentum in the healthcare industry due to cost-effectiveness and increased adherence to the treatment by patients owing to the presence of sensors attached to the inhalers, which stores data measuring the amount of dosage, increasing the efficiency of the drug. Market growth is attributed to the rapid increase in the incidence of respiratory diseases, the rise in air pollution, and growth in healthcare burden, owing to higher cases of asthma and COPD. Amongst the prevalence of COPD and asthma, COPD is expected to be the third leading cause of death globally by 2030. Better treatment options, ease of use, and technological advancements coupled with the increase in adherence rate of patients to smart inhalers are other major factors that drive this market. However, the lack of reimbursement for smart inhalers and limited availability of smart inhalers in developing regions are expected to restrain the global smart inhalers' market growth.
"Amongst product type, Inhalers dominated the global smart inhalers market, with 88.6% share and is projected to dominate the market by 2026."
Based on product type, the report bifurcates the global smart inhalers market into Inhaler (Metered Dose Inhalers, Dry Powder Inhalers) and nebulizers. The market of metered-dose inhalers is expected to grow tremendously at a CAGR of 15.1% during the forecast period 2020-2026, due to the high adoption of these devices.
"Chronic Obstructive Pulmonary Disorder (COPD) indication segment is expected to dominate the use of smart inhalers in 2018, however Asthma indication would grow at highest CAGR growth"
Based on indication, the global smart inhaler market is segmented into Chronic Obstructive Pulmonary Disorder (COPD) and asthma. The COPD occupied the largest share and is expected to maintain its dominance throughout the forecast period 2020-2026 owing to COPD is expected to be the third leading cause of death globally by 2030. The segment generated revenue of US$ 835.5 million in 2018.
"Hospital Pharmacies was the most preferred distribution channel for smart inhalers; however, Online Pharmacies are expected to witness high adoption during the analyzed period"
On the basis of distribution channel, the report segments the global smart inhaler market into Hospital Pharmacies, Retail Pharmacies and Retail Pharmacies. In 2018, Hospital Pharmacies were the most preferred channel of distribution accounting for more than 70% share.
"Amongst end-user, Hospitals & Clinics is anticipated to dominate the Global Smart Inhaler market by 2026."
Based on end-users the global smart inhaler market is segmented into Hospitals & Clinics, Respiratory Care Centre and others. In 2018, Hospitals & Clinics were the largest end-users of smart inhalers and is expected to remain dominance during the analysed period. However, Respiratory Care Centre are expected to witness CAGR growth of 17.7% during 2020-2026 period.
"North America represents as the largest market for smart inhaler globally, followed by Europe and Asia-Pacific"
For a deep-dive analysis of the industry, the study also includes Global regional-level analysis includes major markets of the Smart Inhaler market in North America (US, Canada, Rest of North America), Europe (Germany, UK, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific) and Rest of the world. In 2018, North America generated revenue of US$ 651.0 million and is expected to reach US$ 1,904.8 million by 2026. The dominance is owing to the high prevalence of respiratory disorders and rising old age population along with high awareness among the people.
Competitive Landscape-Top 10 Market Players
Boehringer Ingelheim, Cohero Health, Inc., Omron Corporation, Novartis, AstraZeneca, Teva Pharmaceuticals Industries Ltd., Vectura Group, GlaxoSmithKline, Adherium Limited, 3M are some of the prominent players operating in the Global Smart Inhaler market. Several M&A's along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.
Reasons to buy:
? Current and future market size from 2019 to 2026 in terms of value (US$)
? Combined analysis of deep-dive secondary research and input from primary research through Key Opinion Leaders of the industry
? Country-level details of the overall adoption of Smart Inhaler market and several case studies of the patients who have adopted smart inhalers
? A quick review of overall industry performance at a glance
? In-depth analysis of key industry players
? A detailed analysis of drivers, restraints, key trends and opportunities prevailing in the industry
? Examination of industry attractiveness with the help of Porter's Five Forces analysis and start-ups
? The study comprehensively covers the market across different segments and sub-segments of the technology
? Region/country Covered: North America (US, Canada and Rest of North America), Europe (UK, Germany, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia and Rest of Asia-Pacific), and Rest of World
Customization Options:
UMI understands that you may have your own business need, hence we also provide fully customized solutions to clients. The Global Smart Inhaler market can be customized to the country level or any other market segment.
Table of Contents
1. MARKET INTRODUCTION
1.1 Market Definition 19
1.2 Objective of the Study 19
1.3 Limitation 19
1.4 Stakeholders 19
1.5 Currency used in the Report 20
1.6 Scope of the Global Smart Inhaler Market Study 20
2. RESEARCH METHODOLOGY 21
2.1 Research Methodology adopted for Global Smart Inhaler Market study 21
2.1.1 Main objective of the Global Smart Inhaler Market Study 22
3. REGULATORY FRAMEWORK 23
3.1 General Overview 23
3.1.1 US Regulations for Wearable Medical Devices 23
3.1.1.1 Legal Framework for Medical Device Regulation 23
3.1.1.2 FDA Flexibility on Low-Risk Mobile Applications 24
3.1.1.3 Legal Framework for Health Data Privacy 24
3.1.2 Japan Regulations for Wearable Medical Devices 24
3.1.2.1 List of software Under Regulation 25
3.1.2.2 Legal Framework for Health Data Privacy 25
3.1.3 European Regulations for Wearable Medical Devices 26
3.1.3.1 EU Strict Rules on Medical Device Software 26
3.1.3.2 Legal Framework for Health Data Privacy 27
4. INDUSTRY PERFORMANCE 28
5. EXECUTIVE SUMMARY 30
6. MARKET OVERVIEW 32
6.1 Introduction 32
6.2 Market Dynamics 33
6.2.1 Market Drivers 33
6.2.1.1 Accelerating Geriatric Population 33
6.2.1.2 Increasing Prevalence of Respiratory Disorders 35
6.2.1.3 Rising Air Pollution 36
6.2.1.3.1 Facts About Air Pollution: 38
6.2.1.4 Rising Healthcare Expenditure and Health-Conscious Personals 38
6.2.1.5 Growing Penetration of Smart Phones 42
6.2.2 Market Restraints 43
6.2.2.1 Overall High Cost of Inhalers 43
6.2.2.2 Misusing Data and Data Privacy 44
6.2.2.3 Lack of Awareness 47
6.2.3 Market Trends 47
6.2.3.1 Increasing demand for connected devices 47
6.2.3.2 Significant Growth in IoMT Market 47
7. EMERGENCE OF SMART INHALER MARKET 49
7.1 General Overview 49
7.2 Connected Device as a Solution 55
7.2.1 Potential Benefits of Smart Inhaler 55
7.2.1.1 Patients: 55
7.2.1.2 Healthcare provider: 55
7.2.1.3 Pharmaceutical company: 55
7.3 Partnerships Between Several Pharma and Technology/ Device Companies 56
8. PATIENT CONCERNS REGARDING SMART INHALERS AND CASE STUDIES 57
8.1 The Survey 57
8.2 Case Studies 58
8.2.1 Lyndsey Affected with Poor Asthma Symptoms 58
8.2.2 Jaswinder Seeking Solution for Her Daughter's Asthma 59
8.2.3 Adrian Using Connected Peak Flow for Monitoring Asthma 59
8.2.4 Matthew Worrying About the Worsening of His Asthma 60
9. KEY MARKET INDICATORS 61
9.1 Demand Side Analysis 61
9.2 Supply Side Analysis 63
9.2.1 Product Launch 66
9.2.2 Partnerships 68
9.2.2.1.1 Business Expansion & Investments 68
9.2.3 Merger and Acquisitions 68
9.3 Value Chain Analysis of Smart Inhaler Market 69
10. MARKET INSIGHTS BY PRODUCT 71
10.1 General Overview 71
10.1.1 Inhalers 72
10.1.1.1 Dry Powder Inhaler (DPI) 74
10.1.1.2 Metered Dose Inhaler (MDI) 75
10.1.2 Nebulizers 77
11. MARKET INSIGHTS BY INDICATION 79
11.1 General Overview 79
11.1.1 Chronic Obstructive Pulmonary Disease (COPD) 80
11.1.2 Asthma 81
12. MARKET INSIGHTS BY DISTRIBUTION CHANNEL 83
12.1 General Overview 83
12.1.1 Hospital Pharmacies 84
12.1.2 Retail Pharmacies 85
12.1.3 Online Channel 86
13. MARKET INSIGHTS, BY END-USER 88
13.1 General Overview 88
13.1.1 Hospitals & Clinics 89
13.1.2 Respiratory Care Centre 90
13.1.3 Others 91
14. MARKET INSIGHTS BY REGION/COUNTRY 93
14.1 General Overview 93
14.2 North America Smart Inhaler Market 94
14.2.1 North America Smart Inhalers Market, by Product 94
14.2.2 North America Smart Inhalers Market, by Indication 95
14.2.3 North America Smart Inhalers Market, by Distribution Channel 95
14.2.4 North America Smart Inhalers Market, by End-Users 96
14.2.5 North America Smart Inhalers Market, by Country 96
14.2.5.1 United States Smart Inhaler Market 97
14.2.5.1.1 Key Findings on Healthcare Spending in the US, 2017 98
14.2.5.1.2 US Health Spending by Type of Service or Product, 2017 98
14.2.5.1.3 Health Spending by Major Sources of Funds 99
14.2.5.1.4 US Smart Inhalers Market, by Product 100
14.2.5.1.5 US Smart Inhalers Market, by Indication 101
14.2.5.1.6 US Smart Inhalers Market, by Distribution Channel 101
14.2.5.1.7 US Smart Inhalers Market, by End-Users 102
14.2.5.2 Canada Smart Inhaler Market 102
14.2.5.2.1 Key Facts on Total Hospital Cost, by Health Conditions Canada, 2016 103
14.2.5.2.2 Key Findings on Canada Healthcare Spending, 2018 104
14.2.5.2.3 Key Findings on Hospital sector Spending in Canada, 2018 104
14.2.5.2.4 Canada Smart Inhalers Market, by Product 105
14.2.5.2.5 Canada Smart Inhalers Market, by Indication 106
14.2.5.2.6 Canada Smart Inhalers Market, by Distribution Channel 106
14.2.5.2.7 Canada Smart Inhalers Market, by End-Users 107
14.2.5.3 Rest of the NA Smart Inhaler Market 107
14.2.5.3.1 Key Findings on Healthcare Spending in Mexico, 2016 107
14.2.5.3.2 Rest of NA Smart Inhalers Market, by Product 109
14.2.5.3.3 Rest of NA Smart Inhalers Market, by Indication 110
14.2.5.3.4 Rest of NA Smart Inhalers Market, by Distribution Channel 110
14.2.5.3.5 Rest of NA Smart Inhalers Market, by End-Users 111
14.3 Europe Smart Inhaler Market 111
14.3.1 Europe Smart Inhalers Market, by Product 112
14.3.2 Europe Smart Inhalers Market, by Indication 113
14.3.3 Europe Smart Inhalers Market, by Distribution Channel 113
14.3.4 Europe Smart Inhalers Market, by End-Users 114
14.3.5 Europe Smart Inhalers Market, by Country 114
14.3.5.1 Germany Smart Inhaler Market 115
14.3.5.1.1 Facts on COPD and Asthma in Germany 115
14.3.5.1.2 Germany Smart Inhalers Market, by Product 116
14.3.5.1.3 Germany Smart Inhalers Market, by Indication 116
14.3.5.1.4 Germany Smart Inhalers Market, by Distribution Channel 117
14.3.5.1.5 Germany Smart Inhalers Market, by End-Users 117
14.3.5.2 United Kingdom Smart Inhaler Market 118
14.3.5.2.1 United Kingdom Smart Inhalers Market, by Product 119
14.3.5.2.2 United Kingdom Smart Inhalers Market, by Indication 119
14.3.5.2.3 United Kingdom Smart Inhalers Market, by Distribution Channel 120
14.3.5.2.4 United Kingdom Smart Inhalers Market, by End-Users 120
14.3.5.3 Spain Smart Inhaler Market 121
14.3.5.3.1 Spain Smart Inhalers Market, by Product 121
14.3.5.3.2 Spain Smart Inhalers Market, by Indication 122
14.3.5.3.3 Spain Smart Inhalers Market, by Distribution Channel 122
14.3.5.3.4 Spain Smart Inhalers Market, by End-Users 123
14.3.5.4 France Smart Inhaler Market 123
14.3.5.4.1 France Smart Inhalers Market, by Product 124
14.3.5.4.2 France Smart Inhalers Market, by Indication 125
14.3.5.4.3 France Smart Inhalers Market, by Distribution Channel 125
14.3.5.4.4 France Smart Inhalers Market, by End-Users 126
14.3.5.5 Italy Smart Inhaler Market 126
14.3.5.5.1 Italy Smart Inhalers Market, by Product 127
14.3.5.5.2 Italy Smart Inhalers Market, by Indication 127
14.3.5.5.3 Italy Smart Inhalers Market, by Distribution Channel 128
14.3.5.5.4 Italy Smart Inhalers Market, by End-Users 128
14.3.5.6 Rest of Europe Smart Inhaler Market 129
14.3.5.6.1 Rest of Europe Smart Inhalers Market, by Product 131
14.3.5.6.2 Rest of Europe Smart Inhalers Market, by Indication 131
14.3.5.6.3 Rest of Europe Smart Inhalers Market, by Distribution Channel 132
14.3.5.6.4 Rest of Europe Smart Inhalers Market, by End-Users 132
14.4 Asia-Pacific Smart Inhaler Market 133
14.4.1 Asia-Pacific Smart Inhalers Market, by Product 134
14.4.2 Asia-Pacific Smart Inhalers Market, by Indication 135
14.4.3 Asia-Pacific Smart Inhalers Market, by Distribution Channel 135
14.4.4 Asia-Pacific Smart Inhalers Market, by End-Users 136
14.4.5 Asia-Pacific Smart Inhalers Market, by Country 136
14.4.5.1 China Smart Inhaler Market 137
14.4.5.1.1 China Smart Inhalers Market, by Product 138
14.4.5.1.2 China Smart Inhalers Market, by Indication 139
14.4.5.1.3 China Smart Inhalers Market, by Distribution Channel 139
14.4.5.1.4 China Smart Inhalers Market, by End-Users 140
14.4.5.2 India Smart Inhaler Market 140
14.4.5.2.1 India Smart Inhalers Market, by Product 142
14.4.5.2.2 India Smart Inhalers Market, by Indication 142
14.4.5.2.3 India Smart Inhalers Market, by Distribution Channel 143
14.4.5.2.4 India Smart Inhalers Market, by End-Users 143
14.4.5.3 Japan Smart Inhaler Market 144
14.4.5.3.1 Changing Demographic Structure of Japan 145
14.4.5.3.2 Japan Smart Inhalers Market, by Product 146
14.4.5.3.3 Japan Smart Inhalers Market, by Indication 146
14.4.5.3.4 Japan Smart Inhalers Market, by Distribution Channel 147
14.4.5.3.5 Japan Smart Inhalers Market, by End-Users 147
14.4.5.4 Australia Smart Inhaler Market (2018-2025) 148
14.4.5.4.1 Australia Smart Inhalers Market, by Product 149
14.4.5.4.2 Australia Smart Inhalers Market, by Indication 150
14.4.5.4.3 Australia Smart Inhalers Market, by Distribution Channel 150
14.4.5.4.4 Australia Smart Inhalers Market, by End-Users 151
14.4.5.5 South Korea Smart Inhaler Market 151
14.4.5.5.1 South Korea Smart Inhalers Market, by Product 152
14.4.5.5.2 South Korea Smart Inhalers Market, by Indication 153
14.4.5.5.3 South Korea Smart Inhalers Market, by Distribution Channel 153
14.4.5.5.4 South Korea Smart Inhalers Market, by End-Users 154
14.4.5.6 Rest of Asia-Pacific Smart Inhaler Market (2018-2025) 154
14.4.5.6.1 Rest of APAC Smart Inhalers Market, by Product 155
14.4.5.6.2 Rest of APAC Smart Inhalers Market, by Indication 156
14.4.5.6.3 Rest of APAC Smart Inhalers Market, by Distribution Channel 156
14.4.5.6.4 Rest of APAC Smart Inhalers Market, by End-Users 157
14.5 Rest of World Smart Inhaler Market (2018-2025) 157
14.5.1 Rest of World Smart Inhalers Market, by Product 159
14.5.2 Rest of World Smart Inhalers Market, by Indication 159
14.5.3 Rest of World Smart Inhalers Market, by Distribution Channel 160
14.5.4 Rest of World Smart Inhalers Market, by End-Users 160
15. COMPETITIVE SCENARIO 161
15.1 Porter's Five forces analysis 161
15.1.1 Bargaining Power of Buyers 161
15.1.2 Bargaining power of Supplier 162
15.1.3 Threat of new entrants 162
15.1.4 Availability of Substitute 162
15.1.5 Industry Rivalry 163
15.2 Market Share Analysis, by Company 2019 164
16. TOP COMPANY PROFILES 166
16.1 Boehringer Ingelheim 166
16.1.1 Key Facts 166
16.1.2 Business Description 166
16.1.3 Key Product/Services Offerings 166
16.1.4 Growth Strategy 167
16.1.5 SWOT Analysis 167
16.1.6 Key Financials (2014-2018) 168
16.1.7 Revenue Split 169
16.1.8 Recent Developments 169
16.1.8.1 Product Launches 169
16.1.8.2 Business Expansion and Investments 170
16.2 Cohero Health, Inc. 171
16.2.1 Key Facts 171
16.2.2 Business Description 171
16.2.3 Key Product/Services Offerings 171
16.2.4 Growth Strategy 171
16.2.5 SWOT Analysis 172
16.2.6 Recent Developments 173
16.2.6.1 Product Launches 173
16.2.6.2 Investment 173
16.3 Omron Corporation 174
16.3.1 Key Facts 174
16.3.2 Business Description 174
16.3.3 Key Product/Services Offerings 175
16.3.4 Growth Strategy 175
16.3.5 SWOT Analysis 177
16.3.6 Key Financials (2014-2018) 178
16.3.7 Revenue Split 179
16.4 Novartis 180
16.4.1 Key Facts 180
16.4.2 Business Description 180
16.4.3 Key Product/Services Offerings 180
16.4.4 Growth Strategy 181
16.4.5 SWOT Analysis 182
16.4.6 Key Financials (2014-2018) 183
16.4.7 Revenue Split 184
16.5 AstraZeneca 185
16.5.1 Key Facts 185
16.5.2 Business Description 185
16.5.3 Key Product/Services Offerings 186
16.5.4 Growth Strategy 186
16.5.5 SWOT Analysis 187
16.5.6 Key Financials 188
16.5.7 Revenue Split 189
16.5.8 Recent Developments 189
16.5.8.1 Product Launches 189
16.5.8.2 Business Expansion 189
16.6 Teva Pharmaceuticals Industries Ltd. 190
16.6.1 Key Facts 190
16.6.2 Business Description 190
16.6.3 Key Product/Services Offerings 190
16.6.4 Growth Strategy 191
16.6.5 SWOT Analysis 192
16.6.6 Key Financials (2014-2018) 193
16.6.7 Revenue Split 194
16.6.8 Recent Developments 194
16.6.8.1 Product Launch 194
16.6.8.2 Business Expansion 194
16.7 Vectura Group 195
16.7.1 Key Facts 195
16.7.2 Business Description 195
16.7.3 Key Product/Services Offerings 196
16.7.4 Growth Strategy 197
16.7.5 SWOT Analysis 197
16.7.6 Key Financials 198
16.7.7 Revenue Split 199
16.7.8 Recent Developments 199
16.7.8.1 Product Launches 199
16.7.8.2 Partnership 200
16.8 GlaxoSmithKline 201
16.8.1 Key Facts 201
16.8.2 Business Description 201
16.8.3 Key Product/Services Offerings 201
16.8.4 Growth Strategy 202
16.8.5 SWOT Analysis 203
16.8.6 Key Financials 204
16.8.7 Revenue Split 205
16.8.8 Recent Developments 205
16.8.8.1 Product Launches 205
16.8.8.2 Merger and Acquisitions 206
16.9 Adherium Limited 207
16.9.1 Key Facts 207
16.9.2 Business Description 207
16.9.3 Key Product/Services Offerings 208
16.9.4 Growth Strategy 209
16.9.5 SWOT Analysis 209
16.9.6 Key Financials (2014-2018) 210
16.9.6.1 Revenue Split 211
16.9.7 Recent Developments 211
16.9.7.1 Product Launches 211
16.9.7.2 Partnership 211
16.10 3M 213
16.10.1 Key Facts 213
16.10.2 Business Description 213
16.10.3 Key Product/Services Offerings 214
16.10.4 SWOT Analysis 215
16.10.5 Key Financials 216
16.10.6 Revenue Split 217
16.10.7 Recent Developments 217
16.10.7.1 Product Launches 217
List of Figures
FIG. 1 Scope of the Global Smart Inhaler Market Study 20
FIG. 2 Research Methodology for Global Smart Inhaler Market study 21
FIG. 3 Global Smart Inhalers Market (USD Million), 2018-2026 31
FIG. 4 Graphical Representation of Data Sharing Through Smart Inhaler 32
FIG. 5 Number of Persons aged 65+ years by Geographic Region, 2019 and 2050 (in Millions) 34
FIG. 6 Number of People aged 65 or older per 100 people of working age (15-64), by Region 34
FIG. 7 Ten countries or areas with the highest old-age dependency ratio (65+/20-64), 2019 and 2050 35
FIG. 8 Global Prevalence of Asthma and COPD 36
FIG. 9 Non-communicable Disease (NCD) Deaths Due to Air Pollution (%) 37
FIG. 10 Facts About Air Pollution 37
FIG. 11 World Top Polluted Countries 2018 (PM2.5) 38
FIG. 12 Current expenditure on health, % of GDP (2018) 40
FIG. 13 Current Expenditure on Health, Per Capita, US$ PPP (2017) 41
FIG. 14 Key Facts on Smartphone Market, 2018 42
FIG. 15 Global Total Breached Healthcare Records (2014-2018) 46
FIG. 16 Growth Prediction of Global IoMT Market by Type (US$ billion) 48
FIG. 17 Growth Prediction of Global IoMT Market by Region (US$ billion) 48
FIG. 18 Inhalation Flow Profile Showing the Calibrated Flow Rate (Standard liters Per Minute (l/min) Versus the Inhalation Time in Seconds (s)) 49
FIG. 19 Comparison Showing Drug Deposition When the Drug is Released in the Optimal Timing Window (Left Side) and When the Drug Release is Delayed (Right Side) 50
FIG. 20 Parameters Derived from the Inhalation Airflow Characteristic: Inspired Vital Capacity (IVC) and Peak Inspired Flow Rate (PIF) 51
FIG. 21 Airway Resistance (RAW) Derived from the Calibrated Inhalation Airflow 51
FIG. 22 Spirometer Plot of Flow Rate Versus Inhaled Volume 52
FIG. 23 Schematic Behaviour of PIF, IVC, and RAW 53
FIG. 24 The burden of Asthma and Digital Potential 54
FIG. 25 The Data Flow with Connected Devices 55
FIG. 26 The Data Flow with Connected Devices 56
FIG. 27 Patient's and Company View Regarding the Disease and Connected Devices 57
FIG. 28 Case Example
Boehringer Ingelheim
Cohero Health
Inc.
Omron Corporation
Novartis
AstraZeneca
Teva Pharmaceuticals Industries Ltd.
Vectura Group
GlaxoSmithKline
Adherium Limited
3M